EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Pembrolizumab-induced optic neuropathy – a case report

Eveline Daetwyler, Alfred Zippelius, Peter Meyer, Heinz Läubli

Frontiers in Immunology · 09.05.2023 · 14

DOI: 10.3389/fimmu.2023.1171981 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Immunology, online erschienen am 09.05.2023. Verfasst von Eveline Daetwyler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, University Hospital Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Hodgkin Disease, Optic Nerve Diseases. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitor (ICI) treatment has become important for treating various cancer types, including Hodgkin’s lymphoma. However, ICI can overstimulate the immune system, leading to a broad range of immunological side effects, known as immune-related adverse events (irAEs). Here, we report a case of optic neuropathy caused by pembrolizumab. Case presentation A patient with Hodgkin’s lymphoma received pembrolizumab every three weeks. Twelve days after the sixth cycle of pembrolizumab, the patient was admitted to the emergency department with blurred vision, visual field impairment and altered color perception affecting the right eye. The diagnosis of immune-related optic neuropathy was established. Pembrolizumab was stopped permanently and high-dose steroid treatment was immediately started. This emergency treatment led to a satisfactory binocular vision and an improvement of visual acuity testing results. After another 7 months, the left eye was affected with the same symptoms. At this time, only an extended immunosuppressive therapy consisting of high-dose steroid treatment, plasmapheresis, immunoglobulin treatment, retrobulbar injection of steroids and mycophenolate mofetil, successfully reduced the symptoms.

Conclusions

This case highlights the need for prompt recognition and treatment of rare irAEs, such as optic neuropathy. Urgent treatment with initial high-dose steroid treatment is required to avoid persistent loss of visual acuity. Options for further treatment are mainly based on small case series and case reports. In our case, a retrobulbar injection of steroids in combination with mycophenolate mofetil showed significant success in treating steroid-refractory optic neuropathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hodgkin DiseaseOptic Nerve DiseasesHumansMycophenolic AcidAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

PD-1/L1case reportimmune checkpoint inhibitor (ICI)immune-related adverse event(s)neuropathicoptic neuropathy

Substanzen

pembrolizumabMycophenolic AcidAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Department of Biomedicine, University of Basel, Basel, Switzerland.
  • Eye Clinic, University Hospital Basel, Basel, Switzerland.

Zitieren

APA

Daetwyler, E., Zippelius, A., Meyer, P., & Läubli, H. (2023). Pembrolizumab-induced optic neuropathy – a case report. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1171981

Vancouver

Daetwyler E, Zippelius A, Meyer P, Läubli H. Pembrolizumab-induced optic neuropathy – a case report. Frontiers in Immunology. 2023;14. doi:10.3389/fimmu.2023.1171981

BibTeX
@article{Daetwyler2023,
  author = {Daetwyler, Eveline and Zippelius, Alfred and Meyer, Peter and Läubli, Heinz},
  title = {Pembrolizumab-induced optic neuropathy – a case report},
  journal = {Frontiers in Immunology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fimmu.2023.1171981}
}
Kostenlos starten →